

- Schizoaffective disorder is a somewhat controversial but very common diagnosis; however, there has been very limited study of effective treatments for this disorder, compared to the plethora of well-studied options available for schizophrenia
- Paliperidone palmitate is the first, and currently only, Food and Drug Administration-approved, once-monthly medication to treat schizoaffective disorder.
- Active paliperidone plasma levels are detected at day 1; therefore initial co-administration of oral paliperidone is not necessary, which is both convenient and useful for patients with problems with treatment adherence.
- Registration trials have demonstrated that paliperidone is efficacious for both psychotic and mood symptomatology, both alone and when used with adjunctive mood stabilizers and/or antidepressants.
- Paliperidone palmitate has been demonstrated to delay time to and reduce risk of relapse compared to placebo, when used as monotherapy or with adjunctive therapy.

This summary slide represents the opinions of the authors. No external funding or writing assistance was utilized in the production of this review. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).